Overview of DS patent expiring drugs in the Orange Book of the United States in 2021 (excerpt)

Pharmaceutical patents are the concentrated manifestation of innovation and intellectual property rights in the process of drug research and development, and are a testimony to the birth of innovative drugs

From the perspective of the overall development trend of the pharmaceutical industry, 2020-2030 is the intensive period of global patent drug expiration

In order to promote the development of China’s generic drug industry and give back to the partners of the China Pharmaceutical Industry Information Center (hereinafter referred to as the Information Center), the information center uses its own powerful data platform to collect and sort out some information on core patent expired drugs in 2021 for domestic imitation.

Through the screening of the CPM database of the Information Center, we selected the earliest DS patents (Drug Substance Patents) included in "Approved Drug Products with Therapeutic Equivalence Evaluations" (Approved Drug Products with Therapeutic Equivalence Evaluations, "U.

Core patents expire, but peripheral patents may still be protected: Facing the pressure of generic drugs, many original research drug companies have adopted basic patent strategies, follow-up patent strategies, and formation of patent protection networks to extend the patent protection period of drugs as much as possible

Due to space limitations, we select part of the information of some medicines for readers

1.

Sales status and forecast of original research products over the years

Figure 1 2016-2028E global sales of Aformtro's original products (US$ million, year-on-year growth rate)

Current research and development status

Patent distribution

Figure 2 Distribution of Aformtro's patent companies (number of patents)

Figure 3 Distribution of Arformotero's patent types (number of patents)

Two, bictitgravir + emtricitabine + propofol tenofovir

Basic drug information

Sales status and forecast of original research products over the years

Figure 4 Biquetegravir + emtricitabine + propofol tenofovir (compound) original research product 2018-2027E global sales (million dollars, year-on-year growth rate)

Current research and development status

Patent distribution

Figure 5 Distribution of patented companies of bicotegravir + emtricitabine + propofol tenofovir (number of patents)

Figure 6 The distribution of patent types of bictitgravir + emtricitabine + propofol tenofovir (number of patents)

3.

Original research product sales forecast

Figure 7 Global sales of Bumelanin's original product 2022E-2025E (US$ million, year-on-year growth rate)

Current research and development status

Patent distribution

Figure 8 Distribution of bumelan peptide patent companies (number of patents)

Figure 9 Distribution of bumelan peptide patent types (number of patents)

Four, brivaracetam

Sales status and forecast of the original research over the years

Figure 10 2016-2026E global sales of original Brivaracetam products (US$ million, year-on-year growth rate)

Current research and development status

Patent distribution

Figure 11 Distribution of briracetam patent companies (number of patents)

Figure 12 The distribution of briracetam patent types (number of patents)

instruction

1.

2.

3.

4.